
BiomX Inc. (PHGE) Stock Forecast & Price Target
BiomX Inc. (PHGE) Analyst Ratings
Bulls say
BiomX is a company poised for success as they continue to make progress on their lead assets, BX211 and BX004, which target severe infections in cystic fibrosis and diabetic foot osteomyelitis patients, respectively. The recent positive news from the independent DMC, the resolution of the FDA's hold on the BX004 Phase 2b program, and ongoing recruitment in their BX004 trial highlight the company's potential for success. Additionally, the FDA's guidance on DFI studies provides a clear path for BiomX's development plans and the company's strong financial position and EPS beating their estimates show their capability for sustainable growth.
Bears say
BiomX is a high-risk investment with a negative outlook due to potential challenges in securing funding for its drug development and the risk of failed or inconclusive clinical trials. While the FDA has shown flexibility and support for the company's clinical programs, there is no guarantee of success. Additionally, upcoming dilutive capital raises may negatively impact the stock. However, if the company is able to achieve its projected market penetration and secure partnerships, there is potential for upside to our $26 price target based on the company's two lead phage assets, as well as the potential for additional indications and ex-U.S. opportunities. Overall, the stock remains a speculative investment with significant potential risks.
This aggregate rating is based on analysts' research of BiomX Inc. and is not a guaranteed prediction by Public.com or investment advice.
BiomX Inc. (PHGE) Analyst Forecast & Price Prediction
Start investing in BiomX Inc. (PHGE)
Order type
Buy in
Order amount
Est. shares
0 shares